Oncology Town Hall™: Primary Investigators Present Advancements in the Management of CLL

Overview

Inhibiting signaling pathways with targeted agents has redefined the paradigm of care through multiple lines of therapy in patients with chronic lymphocytic leukemia (CLL). To date, several agents—from monoclonal antibodies, to B cell–receptor and BCL2 inhibitors, to immunomodulators—have been approved for CLL, while additional therapies are currently in development. The rapid pace and sheer volume of therapeutic advances that continue to emerge in the treatment of CLL makes it challenging for clinicians who strive to maintain state-of-the-art care for their patients to keep up with evolving data and apply it to their practices.

This activity will update oncology health care professionals on the most recent data from key abstracts presented at major cancer conferences and place it in clinical context, so that they can assess and apply these findings to their clinical practice and ultimately improve care for their patients with CLL.

Benefits of Attending

• Hear primary investigators present their findings from recent oncology conferences.
• Understand the clinical impact of recent data, and learn how to apply it to your practice.
• Submit your questions to the expert faculty panel.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, and other oncology health care professionals who treat patients with CLL. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of CLL are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify patient and disease factors that aid in personalizing approaches to care for patients with CLL.
• Determine patient characteristics from recently reported and ongoing clinical trials conducted among patients with CLL.
• Evaluate safety and efficacy data from recent clinical trials that impact practice in the care of patients with CLL.
• Place recent clinical trial results in their proper clinical context given evolving treatment paradigms in CLL management.

Physicians' Education Resource^®, LLC (PER^®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource^®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER^® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER^® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER^® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER^®.

Meeting information is accurate at the time of posting.

PER^® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.